Disease Domain | Count |
---|---|
Neoplasms | 3 |
Endocrinology and Metabolic Disease | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Mechanism Mitochondrial complex I (NADH dehydrogenase) inhibitors |
Active Org. ImmunoMet Therapeutics, Inc.Startup [+1] |
Originator Org. ImmunoMet Therapeutics, Inc.Startup |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AMPK agonists [+1] |
Active Org. ImmunoMet Therapeutics, Inc.Startup |
Originator Org. ImmunoMet Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. ImmunoMet Therapeutics, Inc.Startup |
Originator Org. ImmunoMet Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date09 Oct 2017 |
Sponsor / Collaborator ImmunoMet Therapeutics, Inc.Startup |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Lixumistat ( Mitochondrial complex I (NADH dehydrogenase) ) | Melanoma More | Phase 2 |
IM-176 ( AMPK ) | Neoplasms More | Preclinical |
IM-188 | Neoplasms More | Preclinical |
IM-184 | Neoplasms More | Discontinued |
IM-059 | Breast Cancer More | Discontinued |